Antibody-drug conjugates targeting glypican-3 and methods of use thereof
By developing antibody-drug conjugates (ADCs) targeting GPC3, the problem of limited efficacy of existing antibodies in the treatment of diseases such as hepatocellular carcinoma is solved, and efficient inhibition and killing of GPC3-expressing cancer cells is achieved.
CN120225563APending Publication Date: 2025-06-27ZYMEWORKS BC INC
50 Cites 0 Cited by
Patent Information
- Application Number
- CN202380080452.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-12
- Filing Date
- 2023-10-18
- Publication Date
- 2025-06-27
AI Technical Summary
Technical Problem
Existing antibodies targeting GPC3 show limited efficacy in the treatment of diseases such as hepatocellular carcinoma.
Method used
An antibody-drug conjugate (ADC) targeting phosphatidylinositol proteoglycan-3 (GPC3) was developed that contains conjugation of specific anti-GPC3 antibody constructs to camptothecin analogs for targeting cancer cells.
Benefits of technology
By targeting cancer cells expressed by GPC3, ADC can significantly inhibit the proliferation of cancer cells and kill cancer cells, providing a more effective treatment plan.
✦ Generated by Eureka AI based on patent content.
Abstract
Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct bound to human phosphatidylinositol proteoglycan 3 (GPC3) conjugated to a camptothecin analogue of formula (I). The ADCs are useful as therapeutic agents, in particular in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art